AlphAIAlphAI — Financial news for AI agents
grafa.comOCT 21 min read$MRNA

Moderna rises 2.2% on Nasdaq-100 inclusion

Moderna (MRNA) shares rose 2.2% to $193.01 premarket after Nasdaq announced its inclusion in the Nasdaq-100 Index, replacing Warner Bros. Discovery (WBD). The change takes effect on October 9 and may attract passive investment demand. Moderna's market cap is approximately $75 billion.

Original reporting
grafa.com
Published Oct 2, 2026, 9:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 2:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Moderna rises 2.2% on Nasdaq-100 inclusion — source image
Source · grafa.com
Decision brief

The 30-second read

$MRNABullishHigh
01

Why it matters

The announcement caused a 2.2% pre‑market rise, indicating immediate market reaction and setting the tone for the opening session.

02

Market read

The news directly impacts Moderna's share price and indirectly benefits other Nasdaq‑100 constituents and biotech ETFs.

03

What to watch

Potential dilution from future share issuances or upcoming vaccine pipeline news could offset the index‑driven boost.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Nasdaq‑100 inclusion is a routine but material event that often triggers buying from index funds, especially for large‑cap biotech firms like Moderna.

Company-level read

Ticker impact

$MRNABullishHigh confidence
Context

Moderna will be added to the Nasdaq-100 on Oct 9, driving a 2.2% pre‑market price rise as passive funds are expected to buy the stock.

Expected impact

upward pressure as passive funds add shares

Evidence & confidence

Index inclusion typically triggers automatic purchases by ETFs and mutual funds that track the Nasdaq‑100, supporting a short‑term rally.

Market effects

Sector

Other biotech and pharma stocks may see modest spill‑over buying as investors rotate into the sector via the index.

Regional

U.S. equity markets may open slightly higher on the index‑addition news.

Global

Global passive funds tracking the Nasdaq‑100 will adjust holdings, modestly affecting worldwide demand for MRNA.

Counterpoint

What could challenge this read

If the price already priced in the inclusion, the move could be short‑lived and a pull‑back may follow.

Key entities

  • company
    Moderna

    Biotech firm developing mRNA vaccines, now joining the Nasdaq‑100.

  • exchange
    Nasdaq

    Operator of the Nasdaq‑100 index, announced the inclusion.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 3
$MRNAHighAI 8/10

Moderna (MRNA) Surges 37% in September Despite Healthcare Sector

Moderna (MRNA) surged 37.22% in September due to promising Phase 3 results for its personalized mRNA cancer vaccine, outperforming the broader healthcare sector. The company's P/S ratio is 33.44, significantly higher than its historical median of 8.41, reflecting high growth expectations. Moderna remains unprofitable, with a GF Score of 54/100, indicating mixed financial health. Insider activity shows significant selling, while guru ownership is mixed.

gurufocus.com2 min
OCT 2
$NKEHighAI 9/10

Premarket movers: ike tumbles 10%, Synaptics jumps on $5.7B deal

Nike (NKE) fell 9.6% premarket after mixed Q1 results and weak FY guidance. Synaptics (SYNA) rose 13.8% following a revised $5.7B all-cash acquisition deal by onsemi (ON). Moderna (MRNA) gained 2.2% on Nasdaq-100 inclusion. Fair Isaac (FICO) dropped 6.9% on FHFA mortgage data report. MicroStrategy (MSTR) rose 2.7% after Citi raised its price target.

investing.com2 min
OCT 2
$MRNAHighAI 8/10

Why is Moderna stock rallying today?

Moderna (MRNA) stock rose 2.2% in pre-market trading after its addition to the Nasdaq-100 Index, effective October 9. The move, driven by index-linked buying, follows recent volatility, including a Citi analyst downgrade and a 222% surge since August. The stock trades near its 52-week high, with broader market gains also supporting the rally.

investing.com2 min
OCT 2
$MRNAHigh

Moderna wins Nasdaq-100 inclusion, Warner Bros. Discovery out

Moderna (MRNA) will join the Nasdaq-100 index on 9 October 2026, replacing Warner Bros. Discovery (WBD) due to its pending acquisition. Moderna's shares rose 42.12% in 20 trading days, driven by positive trial data for a melanoma vaccine, despite reporting net losses. WBD's exit is due to its merger with Paramount Skydance, not underperformance.

financial-news.co.uk2 min
OCT 2
$MRNAMed

Moderna (MRNA) to Join Nasdaq-100 as Warner Bros. Discovery Exit

Nasdaq announced Moderna (MRNA) will join the Nasdaq-100 Index, replacing Warner Bros. Discovery (WBD) on October 9. Moderna's P/S ratio is 33.22, well above its historical median of 8.41, reflecting high growth expectations despite its unprofitability. The company's GF Score is 56, indicating moderate fundamental quality. Insider activity shows no purchases and $64.6M in sales over the past year. Moderna's market cap is approximately $75.43B.

gurufocus.com2 min